Intellectual Property,
Health Care & Hospital Law,
Civil Litigation
Apr. 19, 2021
Allele argues urgency doesn’t excuse rival biotech firms infringing
Pfizer and BioNTech sought to dismiss the lawsuit last month, arguing that Allele’s legal action will become another burden as they continue to work on the vaccine.
Pfizer can't use pending license applications or emergency use authorizations for its COVID-19 vaccine as excuses to continue infringing on a patent while making billions in profits, a biopharmaceutical company rival said Friday, urging a federal judge in San Diego not to dismiss its case.
Plaintiff Allele Biotechnology sued Pfizer Inc. and BioNTech last fall, claiming patent infringement. The complaint said the defendants used All...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In